TERBUNY, RUSSIA--(Marketwired - Aug 2, 2013) - The success of Rafarma Pharmaceuticals, Inc. (
The new facility will be located near Rafarma's already-operating pharmaceutical plant in Terbuny in the Lipetsk region of Russia, a few hours south from Moscow. Rafarma and the dialysis facility plan to work in close cooperation in the development of dialysis-specific products.
Terbuny is part of a special economic development region to promote economic growth and jobs in the area. For building and maintaining its facilities in Terbuny, as well as hiring local residents, Rafarma enjoys specific government incentives which enhance its bottom line.
Oleg Korolyov, Governor of the Lipetsk region, specifically lauded this latest development in an article published at news.mail.ru in an article which can be read here: http://news.mail.ru/inregions/center/48/economics/14019946/
CEO Dave Anderson stated: "Rafarma was one of the first to build and operate in Terbuny, and the company's success looks to be the start of a new biotech hub in Russia. Rafarma is not only committed to growth as a company, but also to the development of Terbuny and its local economy and residents."
About Rafarma Pharmaceuticals, Inc.
Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.
For more information on Rafarma Pharmaceuticals, visit: http://RAFA.QualityStocks.net
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.
- Health Care Industry
Rafarma Pharmaceuticals, Inc.